光热疗法（PTT）是一种在临床应用中备受期待的癌症治疗策略，具有安全便捷的手术程序和对浅表肿瘤优异的治疗效果。然而，单一的光热疗法很难完全消除肿瘤细胞，容易在后期出现肿瘤复发和转移。化疗-光热协同疗法可以通过系统化疗进一步杀死光热疗法后的残余肿瘤细胞，克服这些缺点。然而，化疗药物的剧毒性也是一个需要解决的问题，比如蒽环类药物引起的心脏毒性。本文选取聚多巴胺纳米粒子（PDA）作为化疗药物多柔比星（DOX）的载体，构建了一种通用的PDA（DOX）纳米平台，用于针对乳腺癌的化疗-光热协同疗法，并同时减轻DOX引起的心脏毒性（DIC）。PDA优异的光热性能用于实现肿瘤的热消融。DOX通过化疗杀死残余和隐匿的远处肿瘤。此外，PDA（DOX）纳米粒子显著缓解DIC，这要归功于PDA的优异抗氧化酶活性。化疗组的实验数据表明，PDA（DOX）组的结果明显优于DOX组。本研究不仅能有效抑制癌症，还能巧妙地减轻DIC，为乳腺癌的协同治疗带来新的视角。

Photothermal therapy (PTT) is a highly clinical application promising cancer treatment strategy with safe, convenient surgical procedures and excellent therapeutic efficacy on superficial tumors. However, a single PTT is difficult to eliminate tumor cells completely, and tumor recurrence and metastasis are prone to occur in the later stage. Chemo-photothermal synergistic therapy can conquer the shortcomings by further killing residual tumor cells after PTT through systemic chemotherapy. Nevertheless, chemotherapy drugs' extreme toxicity is also a problematic issue to be solved, such as anthracycline-induced cardiotoxicity. Herein, we selected polydopamine nanoparticles (PDA) as the carrier of the chemotherapeutic drug doxorubicin (DOX) to construct a versatile PDA(DOX) nanoplatform for chemo-photothermal synergistic therapy against breast cancer and simultaneously attenuated DOX-induced cardiotoxicity (DIC). The excellent photothermal properties of PDA were used to achieve the thermal ablation of tumors. DOX carried out chemotherapy to kill residual and occult distant tumors. Furthermore, the PDA(DOX) nanoparticles significantly alleviate DIC, which benefits from PDA's excellent antioxidant enzyme activity. The experimental data of the chemotherapy groups showed that the results of the PDA(DOX) group were much better than the DOX group. This study not only effectively inhibits cancer but tactfully attenuates DIC, bringing a new perspective into synergistic therapy against breast cancer.© 2023. BioMed Central Ltd., part of Springer Nature.